Morningstar Rating

Stock Research and Analysis

by Debbie S. Wang

Bulls Say

Hologic was first to market with an FDA-approved 3D mammography platform in the United States, giving it a considerable head start against General Electric and Siemens.
Hologic controls the lion’s share of the U.S. liquid-based Pap market, and the Gen-Probe acquisition catapulted the firm into number one positions in testing for chlamydia, gonorrhea, and blood screening.
Hologic is establishing a firm presence in emerging markets, particularly China, which should provide new growth avenues as a growing middle class and aging population necessitate the firm’s services. Read more 

Bears Say

The Pap smear market is in secular decline and could weigh on Hologic’s results beyond 2014 should it take longer than expected for volume to stabilize.
It remains to be seen whether CMS' level of reimbursement for breast tomosynthesis will be lucrative for Hologic’s customers.
Despite Hologic’s full pipeline and best efforts, a high degree of clinical and regulatory risk surrounds its products. The regulatory path to approval can be an expensive, time-consuming, and fruitless process. Read more 


We award Hologic standard marks for stewardship. The firm announced in December 2013 that Stephen MacMillan would replace Jack Cumming as CEO, who had returned to the role in July after having previously served in that capacity from 2001 to 2009. MacMillan   Read more 


Hologic manufactures proprietary products for the health-care needs of women. The company operates in four segments: diagnostics (48% of sales), breast health (36%), surgical   Read more 

First Name
Last Name
Email Address
Zip Code
Create Password
Verify Password
(6-15 characters; case sensitive)

Health Care a Leader in Moat Stocks 
Watch more 

Premium Membership

View all of our analyst reports with a free trial to Premium.